1Rinne UK,Laraen JP,Siden,et al.Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations[J].Neurology,1998,(51):1309-1314.
2Stocchi F,Olanow CW.Conlinuous dopaminergic stimulation in early and advanced Parkinson's disease[J].Neurology,2004,62:556-563.
3Hauser RA,Hubble JP,Truong DD,et al.Randomized trial of the adenosine A(2A)receptor antagonist istradefylline in advanced PD[J].Neurology,2003,61(3):297-303.
4Ames BN, Shigenaga MK, Hagen TM. Oxidants, antloxidants, and the degenerative diseases of aging. Proc Nad Acad Sci USA,1993,90:7915-7922.
5Sanchez-Ramos J,Overvik E ,Ames B. A marker of oxyradical-mediated DNA damage (8-hydroxy-2 '-deoxyguanosine ) is increased in nigrostriatum of Parkinson's disease brain. Neurodegeneration, 1994,3 : 197- 204.
6Olanow CW,Wans BL, Koller WC. An algorithm ( decision tree) for the management of Parkinson's disease ( 2001 ) : Treatment Guidelines. Neurology ,2001,56 ( suppl 5 ) : S1 -S88.
7Hristova AH,Koller W C. Early Parkinson's Disease:What is the Best Approach to Treatment. Drug & Aging,2000,17:165-181
8Kondo T. Initial therapy for Parkinson's disease:levodopa vs. dopamine receptor agonists. J Neurol,2002,249 (Suppl 2) : Ⅱ25-Ⅱ29.
9Ziegler M,-Castro-Caldas A,Del Signora S,et al. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study. Mov Disord, 2003,18:418-425.
10Stocchi F, Olanow CW. Continuous dopaminergic stimulation in early and advanced Parkinson's disease. Neurology,2004,62 : S56-S63.
